Caplin Point Laboratories: US Steriles and Latin America drive growth pipeline

Investment View and Valuation

In its August 13, 2026 result update, ICICI Direct Research retained its BUY recommendation on Caplin Point Laboratories. The broker cited well-planned execution across Latin America and the US, a healthy product pipeline and ongoing capacity expansion.

The stock was trading at a CMP of Rs 2,400 against ICICI Direct’s target price of Rs 2,840. The broker values the company at 26 times FY28E EPS of Rs 109.3.

Export-Led Business Profile

Caplin Point Laboratories derives almost all of its revenue from exports. Emerging Markets, comprising Latin America and the Rest of World, account for 79 per cent of revenue, while the US contributes 21 per cent.

• In Latin America, around 60 per cent of products are manufactured in-house and around 40 per cent are outsourced.
• Of the outsourced products, 24 per cent are sourced from China and 76 per cent from Indian vendors.
• Caplin Steriles primarily serves the US and other regulated markets.

Q1 FY27 Financial Performance

Reported Q1 FY27 operating income increased 19.6 per cent year-on-year and 1.7 per cent quarter-on-quarter to Rs 610.4 crore. Growth was led by Caplin Steriles, mainly the US business, and by the legacy Latin America business.

US revenue increased around 26 per cent year-on-year to Rs 134 crore across the B2C and B2B models. Legacy Latin America revenue grew 18 per cent to around Rs 476 crore, aided by Central American tender wins and large tender shipments, including El Salvador.

EBITDA margin expanded to 35.0 per cent, supported by lower other expenditure, which declined by 245 basis points year-on-year as a proportion of revenue. Reported PAT increased 18.8 per cent year-on-year to Rs 179.1 crore.

Latin America Growth Outlook

Management described Latin America as Caplin Point Laboratories’ most dependable growth engine, supported by its distribution network, supply-chain consistency and market knowledge. Chile and Central America continue to show healthy tender and private-market traction.

The company intends to increase its focus on private markets in larger geographies, where generic competition is lower, and is expanding into oncology, branded generics and new geographies. It is evaluating the acquisition of a Mexican distribution company and has acquired land for a future Mexico manufacturing facility.

Management indicated that local manufacturing could provide an approximately 16 per cent pricing advantage in government tenders.

US Steriles and Product Pipeline

ICICI Direct highlighted momentum from specialty launches in injectable bags, ophthalmic emulsion, injectable emulsion and plastic vial products. Caplin Point Laboratories plans to launch 15 US products in niche injectable, PP vial and IV bag segments.

• The company may acquire third-party ANDAs and outsource selected in-house products to contract manufacturing organisations to optimise plant utilisation.
• It has developed and filed 60 US ANDAs independently and with partners, with 59 approvals disclosed in the report.
• The company is working on a portfolio of more than 55 simple and complex injectable and ophthalmic products for filing over the next three to four years.
• Management said 39 sterile products have been commercialised.
• Existing sterile facilities are largely booked until February 2027, while the seventh sterile line should start within six to seven months.
• Five additional lines are expected at the Phase III facility by around FY28.

Capacity Expansion and Strategic Initiatives

Caplin Point Laboratories has planned Rs 1,000 crore of expansion capex, of which around 50 per cent has been spent. The balance is expected to be invested over the next 18 to 24 months.

Projects include new Caplin Steriles lines, a Latin America-focused plant, general and oncology API facilities, oncology OSD and injectables capacity, and a new OSD facility. The expansion is being funded through internal cash generation without external debt.

GLP-1 products remain under registration and have not yet contributed commercially. The company is also exploring biosimilar partnerships with Chinese companies and developing API capabilities for backward integration.

Financial Estimates

Key Risks and Watchpoints

• Regulatory risk: Increasing US revenue contribution could heighten regulatory exposure.
• Latin America execution risk: Growth could be affected by a slower-than-expected ramp-up in larger Latin American markets.
• Working capital: Operating cash flow was temporarily affected by strategic inventory and receivables build-up related to government supplies. Receivables are expected to normalise by Q3 FY27.